摘要
目的:制备胸腺五肽(TP-5)微球注射剂,考察不同制备方法对微球性质的影响。方法:以乳酸-羟基乙酸共聚物[poly(lactide-co-glycolide),PLGA]为包裹材料,分别采用复乳法(W/O/W)、固体/油/油法(S/O/O)和固体/油/水法(S/O/W)制备TP-5微球。以微球形态、粒径、微球载药量以及包封率、体外释药曲线等作为微球的质量评价指标,选择合适的制备方法。结果:W/O/W法制备出的TP-5微球流动性良好,形态圆整,平均粒径为(22.14±0.28)μm,微球的包封率为(54.2±3.1)%,突释为(24.3±0.49)%,28d的累积释放量在90%以上。结论:采用复乳法,可以制备含TP-5的PLGA微球。
OBJECtIVE To prepare poly（lactic-co-glycolic acid）（PLGA） rnierospheres of thymopentin （TP-5） and evaluate its characters. METHODS TP-5 microspheres were prepared by different preparation methods （W/O/W, S/O/O and S/O/W method） and characterized for encapsulation efficiency by high-performance liquid chromatography （HPLC）, particle size by laser particle size analyzer, surface morphology by scanning electron microscopy （SEM）. RESISTS Rate studies in vitro were also conducted. RESULTS TP-5 was successively encapsulated into PLGA microspheres by W/O/W methods. The average size was （22. 14±0. 28）μm. TP-5 encapsulation efficiency was （54. 2 ± 3.1 ） %. The burst release in 24 hours was （24. 3 ±0. 49）% and the cumulated release in 28 days was up to 90 % in vitro. CONCLUSION TP-5 can be encapsulated into PLGA microspheres by W/O/W methods and can be useful for the controlled delivery of TP-5.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2010年第8期660-662,共3页
Chinese Journal of Hospital Pharmacy
